Intellia Therapeutics Inc (NASDAQ:NTLA) traded down 6.1% on Tuesday . The company traded as low as $21.25 and last traded at $21.59. 749,500 shares changed hands during trading, an increase of 119% from the average session volume of 342,112 shares. The stock had previously closed at $23.00.

Several brokerages have recently commented on NTLA. Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a report on Tuesday, August 29th. Barclays restated a “buy” rating on shares of Intellia Therapeutics in a research report on Sunday, November 5th. ValuEngine cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Zacks Investment Research raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Jefferies Group reissued a “buy” rating and issued a $36.00 price target on shares of Intellia Therapeutics in a report on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $30.17.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The firm had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The business’s revenue was up 49.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.22) EPS. equities research analysts predict that Intellia Therapeutics Inc will post -1.68 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Intellia Therapeutics by 10.2% during the second quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock worth $15,957,000 after purchasing an additional 92,580 shares during the period. GMT Capital Corp acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $8,214,000. Granahan Investment Management Inc. MA boosted its position in shares of Intellia Therapeutics by 7.0% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock worth $7,111,000 after acquiring an additional 18,784 shares in the last quarter. Ark Investment Management LLC boosted its position in shares of Intellia Therapeutics by 118.9% during the 2nd quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock worth $2,797,000 after acquiring an additional 94,960 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Intellia Therapeutics by 52.0% during the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after acquiring an additional 56,363 shares in the last quarter. 49.53% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/12/07/intellia-therapeutics-ntla-stock-price-down-6-1.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.